HOME >> BIOLOGY >> NEWS
Researchers identify genetic mutation that may alter tumor cell proliferation

Indianapolis, July 4, 2007 -- Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) today announced finding a novel recurring mutation of the gene AKT1 in breast, colorectal and ovarian cancers. The altered form of AKT1 appears to cause tumor cell proliferation and may play a role in making cells resistant to certain types of therapies. The findings are reported in an advance online publication (AOP) of the journal Nature.

The PI3-Kinase/AKT pathway is among the most commonly activated cellular pathways in human cancers and members of this pathway are among the most frequently targeted for new cancer drug discovery efforts. Activation of this pathway results in cancer cell growth and cell survival. Although AKT1 is central to pathway activation, its role in cancer has been that of an intermediary between mutated upstream regulatory proteins and downstream survival signaling proteins. This is the first evidence of direct mutation of AKT1 in human cancer tumors: it was discovered in clinical samples from cancer patients, yet has never been detected in cancer cell lines.

This discovery is a seminal finding in cancer biology that confirms AKT1 as an oncogene in breast, colorectal and ovarian cancer. The mutation alters the electrostatics of binding pocket in the pleckstrin homology domain, the portion of the enzyme that docks with phospholipids on the cell membrane, said Kerry L. Blanchard, PhD, MD, Executive Director, Discovery Biology Research, Eli Lilly & Company.

To identify the AKT1 mutation, the researchers analyzed 150 tumor samples from patients with either breast, colorectal or ovarian cancer (50 samples from each tumor type). Analysis of the data showed that 8 percent of breast, 6 percent of colorectal and 2 percent of ovarian tumors had the AKT1 mutation in the samples that were screened in their study.

Recently, molecular features such as the AKT1 mutation are
'"/>

Contact: Amy Erickson
aerickson@tgen.org
602-343-8522
The Translational Genomics Research Institute
4-Jul-2007


Page: 1 2 3

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers discover method for identifying how cancer evades the immune system
9. Researchers use adult stem cells to create soft tissue
10. Researchers find gene that spurs development of the epididymis
11. Researchers isolate new risk marker for overweight children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/30/2020)... Calif. (PRWEB) , ... May 29, 2020 , ... ... enabler of digital transformation for enterprises globally, has collaborated with EchoNous Inc. to ... FDA. It can measure systolic heart function, which has been clinically tested ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology company developing ... engagers and TCR-based therapeutics, has implemented Genedata Biologics ® within their ...
(Date:5/21/2020)... SCOTTSDALE, Ariz. (PRWEB) , ... May 20, 2020 , ... ... justice, and remove danger for all of us. The positions of these men and ... as from the defense for not following rules precisely. Officers have always had to ...
Breaking Biology News(10 mins):
(Date:5/14/2020)... ... May 12, 2020 , ... ... research, is bringing together thousands of industry leaders, clinicians, research scientists, medical professionals ... plenary speakers, Carl June, MD, Director of the Center for Cellular Immunotherapies at ...
(Date:5/5/2020)... ... ... ProductLife Group has marked the next phase in its global ... years at Altran, where he was Group VP of Life Sciences and Head of ... Xavier was involved in his early career in the development of new medical devices ...
(Date:4/22/2020)... CAMBRIDGE, Mass. (PRWEB) , ... April 20, 2020 ... ... with US offices in Cambridge, MA, announced today that Omixon’s founder and chairman ... early commercialisation of Omixon’s flagship product Holotype HLA since 2014 before stepping into ...
(Date:4/7/2020)... ... April 06, 2020 , ... ... the life sciences industry, has announced the release of at-home virtual learning resources ... priority is the health and safety of our employees as we continue to ...
Breaking Biology Technology:
Cached News: